Evidence map›Paper›PMID 42903016›Full record

ArticleInternational journal of MS care2024

Designing Well-Being Intervention Trials for People With Progressive Multiple Sclerosis: The Importance of Understanding Usual Care Comparators.

Marcia Finlayson, Silvia Poli, Federico Bozzoli, Giampaolo Brichetto, Lars Bø, Isolde Martina Busch, Ulrik Dalgas, Nikos Evangelou, Amanda Farrin, Jennifer Freeman and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of MS care, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Marcia FinlaysonSchool of Rehabilitation Therapy, Faculty of Health Sciences, Queen's University, Kingston, ON, Canada.
Silvia PoliDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Italy.
Federico BozzoliPatient and Public Involvement Partner, Italian MS Society, Scientific Research Area, Genoa, Italy.
Giampaolo BrichettoExecutive Board, Rehabilitation in Multiple Sclerosis Italian MS Society Rehabilitation Center, Genoa, Italy Scientific Research Area, Italian MS Foundation, Genoa, Italy.
Lars BøDepartment of Neurology, Haukeland University Hospital, Bergen, Norway University of Bergen, Bergen, Norway.
Isolde Martina BuschDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Italy.
Ulrik DalgasExercise Biology, Department of Public Health, Aarhus University, Aarhus, Denmark.
Nikos EvangelouFrom the Departments of Mental Health and Clinical Neurosciences.
Amanda FarrinLeeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
Jennifer FreemanFaculty of Health, University of Plymouth, Plymouth, UK.
Helena JidborgPatient and Public Involvement Partner, UK.
Daphne KosNational MS Center Melsbroek (AD, DK), Melsbroek, Belgium.ORCID https://orcid.org/0000-0002-8641-054X
Claudia H MarckThe Melbourne School of Population and Global Health, The University of Melbourne, Australia.ORCID https://orcid.org/0000-0002-3173-1522
Daniel OntanedaSchool of Rehabilitation Therapy, Faculty of Health Sciences, Queen's University, Kingston, ON, Canada.
Jessica PoddaFrom Scientific Research Area, Italian Multiple Sclerosis Foundation, Genoa, Italy (JP, MMU, AT, LP, MMB, GB, MP).ORCID https://orcid.org/0000-0002-9327-9148
Michela RimondiniDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Italy.
Polly SwainResearch and Innovation, Nottingham University Hospitals NHS Trust, Nottingham, UK School of Health, Education, Policing and Sciences, University of Staffordshire, Stoke-on-Trent, UK.
Emma TallantyreDivision of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, South Wales, United Kingdom.
Lauren A TaylorDepartments of Mental Health and Clinical Neurosciences, School of Medicine, University of Nottingham, Nottingham, UK.
Roshan das NairExecutive Board, Rehabilitation in Multiple Sclerosis Department of Health, SINTEF, Trondheim, Norway University of Nottingham, Nottingham, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Well-being captures an individual's capacity to lead a meaningful and engaged life. Interventions to address well-being go beyond managing symptoms or supporting daily activity performance. Designing trials to evaluate the effectiveness of such well-being interventions can be challenging. One such challenge is determining what the comparator or control arm should be. Several trials of complex interventions use usual care as a comparator, but this can be particularly challenging when planning trials across multiple countries and health care systems. Therefore, trial design decisions must be informed by a good understanding of what constitutes usual or routine well-being interventions across locations. Our international, multidisciplinary team's efforts to develop this understanding across our 8 countries found that efforts to support the well-being of people with progressive multiple sclerosis vary widely. This variability emphasizes the importance of having a consistent way to collect data and report on the components of usual well-being care to inform trial design.

Indexed as

trial designusual carewell-being

Identifiers

PMID42903016
PMCPMC13629445

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.